Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Current Liabilities (2020 - 2025)

Rapid Micro Biosystems' Total Current Liabilities history spans 6 years, with the latest figure at $18.5 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 5.25% to $18.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 million, a 5.25% increase, with the full-year FY2025 number at $18.5 million, up 5.25% from a year prior.
  • Total Current Liabilities hit $18.5 million in Q4 2025 for Rapid Micro Biosystems, up from $16.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RPID hit a ceiling of $19.0 million in Q4 2022 and a floor of $12.8 million in Q2 2022.
  • Historically, Total Current Liabilities has averaged $16.2 million across 5 years, with a median of $16.0 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: increased 16.86% in 2021 and later dropped 20.34% in 2022.
  • Tracing RPID's Total Current Liabilities over 5 years: stood at $18.2 million in 2021, then rose by 4.87% to $19.0 million in 2022, then dropped by 0.34% to $19.0 million in 2023, then decreased by 7.48% to $17.6 million in 2024, then grew by 5.25% to $18.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for RPID at $18.5 million in Q4 2025, $16.5 million in Q3 2025, and $16.4 million in Q2 2025.